[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356827-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356827-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","immunohistochemical-biomarkers-to-predict-adjuvant-chemotherapy-response-in-patients-with-early-breast-cancer-in-the-matador-trial","Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial","","Background: Intensified anthracycline-based regimens using taxanes have comparable efficacy in unselected high-risk early breast cancer, but biomarkers linked to taxane resistance have not been used clinically. A predictive biomarker is needed to personalize treatment. Methods: In the randomized MATADOR trial, 664 pT1-3 pN0-3 patients received TAC or ddAC, and IHC protocols assessed 13 proposed biomarkers in 577 high-risk patients. Results: TN EZH2high tumors showed improved RFS after TAC, whereas EZH2low improved after ddAC; TUBB effects depended on including sTILs. Conclusions: TN EZH2low benefits more from ddAC, EZH2high favors TAC, and high tubulin expression may predict docetaxel benefit when adjusting for sTILs; further validation is required.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/immunohistochemical-biomarkers-to-predict-adjuvant-chemotherapy-response-in-patients-with-early-breast-cancer-in-the-matador-trial/356827/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/immunohistochemical-biomarkers-to-predict-adjuvant-chemotherapy-response-in-patients-with-early-breast-cancer-in-the-matador-trial/356827.png","ImageObject",300,407,{"name":42,"@type":43},"Đào","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What clinical problem does the MATADOR trial biomarker study address?","Question",{"text":63,"@type":64},"It evaluates whether immunohistochemical biomarkers can predict response to adjuvant taxane-containing chemotherapy, since current clinical practice lacks predictive markers for taxane benefit or resistance in early breast cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were patients treated and which biomarkers were tested?",{"text":68,"@type":64},"In MATADOR, 664 patients with pT1-3 pN0-3 breast cancer received TAC or ddAC, and immunohistochemistry assessed 13 previously proposed biomarkers across 577 clinical high-risk patients.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study find about EZH2 and TUBB in treatment response?",{"text":72,"@type":64},"In triple-negative disease, EZH2high tumors had better RFS after TAC, while EZH2low tumors improved after ddAC. For TUBB, outcome differences emerged when stromal tumor-infiltrating lymphocytes (sTILs) were included in the model.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356827,1791096525,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":115,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144},1374402968488,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","The Breast 87 (2026) 104749  \nContents lists available at ScienceDirect  \nThe Breast  \njournal [homepage:](homepage: www.journals.elsevier.com/the-breast)[ www.journals.elsevier.com/the-breast](homepage: www.journals.elsevier.com/the-breast)  \n| Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial (BOOG 2005-02)\u003Cbr>Mark Opdama , Nigel Ulteea , Jill J.J. Geenen b,c, Annelot G.J. van Rossuma , Ingrid A.M. Mandjesd, Sara Balduzzie , Ingrid Hofland f, Jelle Wesseling a,g,h,\u003Cbr>Renee X. Menezes i,j , Hendrika M. Oosterkampk, Sabine C. Linn a,l,m,* , the MATADOR trialists' group for the Dutch Breast Cancer Research Group (BOOG)\u003Cbr>a Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands b Division of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands c Department of Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands d Data Center, Netherlands Cancer Institute, Amsterdam, the Netherlands\u003Cbr>e Biometrics Division, Netherlands Cancer Institute, Amsterdam, the Netherlands\u003Cbr>f Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, the Netherlands g Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands\u003Cbr>h Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands i Biostatistics Centre, The Netherlands Cancer Institute, Amsterdam, the Netherlands\u003Cbr>j Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands\u003Cbr>k Department of Medical Oncology, Haaglanden Medisch Centrum, The Hague, the Netherlands l Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands m Department of Pathology, University Medical Center, Utrecht, the Netherlands |  |  | |\n| --- | --- | --- | --- |\n| A R T I C L E I N F O |  | A B S T R A C T |  |\n| Keywords:\u003Cbr>Early breast cancers\u003Cbr>Prognostic and predictive biomarkers Taxanes\u003Cbr>EZH2\u003Cbr>Tubulins |  | Background: Intensified anthracycline-based regimens are as effective as standard anthracycline-based chemotherapy with taxanes in unselected high-risk patients with early breast cancer and come with their own toxicity profiles. Many biomarkers linked to taxane resistance have been identified, but none are used clinically. A predictive biomarker for taxane resistance or sensitivity would help personalise treatment.\u003Cbr>Methods: In the randomised controlled trial MATADOR (ISRCTN61893718), 664 patients with pT1-3, pN0-3 breast cancer were treated with either docetaxel, doxorubicin, and cyclophosphamide (TAC) or dose-dense schedule of doxorubicin and cyclophosphamide (ddAC). IHC protocols for 13 previously proposed biomarkers (ABCB1, AR, BCL2, CyclinD1, EZH2, GSTP1, pH2AX, Ki67, MAPT, P53, Thioredoxin, TUBB, and TUBB3) were tested in all 577 clinical high-risk patients. The prognostic and predictive value was assessed in the total group, and in the hormone receptor-positive HER2-negative and in the triple-negative (TN) subgroup.\u003Cbr>Results: Patients with TN EZH2high tumours have improved RFS after TAC treatment (n = 83 adjusted hazard ratio [adjHR] 0.35 [0.14–0.83]), while with EZH2low RFS improved after ddAC (n = 16 adjHR 6.31 [0.79–50.5]; P interaction0.01). Similar findings are observed for TUBB when stromal tumour-infiltrating lymphocytes (sTILs) are included in the model. TUBB high have improved outcome after TAC treatment (n = 48 adjHR 0.26 [0.08–0.80]), while for TUBBlow improved with ddAC (n = 47 adjHR 1.94 [0.58–6.50]; P interaction0.03).\u003Cbr>Conclusions: Patients with TN EZH2low tumours benefit more from ddAC, while EZH2high have a better outcome after TAC. High tubulin expression may predict docetaxel benefit if adjusted for sTILs. Further research with more patients is needed to find the best use of these biomarkers.\u003Cbr>Clinical trial identification: MATADOR, ISRCTN61893718, BO","cbCaipf65RXm2kNR","https://ap.wps.com/l/cbCaipf65RXm2kNR","pdf",10852707,"English","# Article info\n## Abstract\n### Keywords\n# Introduction\n## Clinical context and rationale\n## Need for predictive biomarkers","[{\"question\":\"What clinical problem does the MATADOR trial biomarker study address?\",\"answer\":\"It evaluates whether immunohistochemical biomarkers can predict response to adjuvant taxane-containing chemotherapy, since current clinical practice lacks predictive markers for taxane benefit or resistance in early breast cancer.\"},{\"question\":\"How were patients treated and which biomarkers were tested?\",\"answer\":\"In MATADOR, 664 patients with pT1-3 pN0-3 breast cancer received TAC or ddAC, and immunohistochemistry assessed 13 previously proposed biomarkers across 577 clinical high-risk patients.\"},{\"question\":\"What did the study find about EZH2 and TUBB in treatment response?\",\"answer\":\"In triple-negative disease, EZH2high tumors had better RFS after TAC, while EZH2low tumors improved after ddAC. For TUBB, outcome differences emerged when stromal tumor-infiltrating lymphocytes (sTILs) were included in the model.\"}]","Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial | PDF",1790127532,23]